News
REGN
904.35
+0.16%
1.45
Democratic lawmakers seen probing Trump drug pricing deals come January
Seeking Alpha · 1d ago
Regeneron Updates Key PNH Combination Study: What REGN Investors Should Know
TipRanks · 1d ago
Regeneron (REGN) Stock May Trade At A Discount Following Strong Q3 Earnings
Simply Wall St · 2d ago
Regeneron Advances ALN-CIDEB Into Phase 3 Liver Disease Study
TipRanks · 2d ago
BofA adds TMUS, REGN to Value 10 list, leaves Growth 10 untouched
Seeking Alpha · 3d ago
Why Regeneron (REGN) Might be Well Poised for a Surge
NASDAQ · 3d ago
REGN vs. ILMN: Which Stock Is the Better Value Option?
NASDAQ · 3d ago
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Earnings Beat
Simply Wall St · 3d ago
Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...'
Benzinga · 4d ago
How health care is on the ballot in the midterms
Seeking Alpha · 4d ago
Analysts Offer Insights on Healthcare Companies: Azora Therapeutics (AZR), Regeneron (REGN) and InflaRx (IFRX)
TipRanks · 4d ago
Regeneron and Sanofi Update Long-Term Pediatric Dupixent Study
TipRanks · 4d ago
Regeneron Pharmaceuticals (REGN) Could Be 11% Overvalued Following Its Earnings Beat
Simply Wall St · 4d ago
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC’s ‘Final Trades’
Benzinga · 5d ago
ValuEngine Weekly Market Commentary
Seeking Alpha · 5d ago
Regeneron Pharma Is Maintained at Market Perform by Leerink Partners
Dow Jones · 5d ago
Regeneron Pharma Price Target Raised to $997.00/Share From $835.00 by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997
Benzinga · 5d ago
Regeneron Pharma Price Target Raised to $812.00/Share From $756.00 by Bernstein
Dow Jones · 5d ago
Regeneron Pharma Is Maintained at Market Perform by Bernstein
Dow Jones · 5d ago
More
Webull provides a variety of real-time REGN stock news. You can receive the latest news about Regeneron Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.